Could a routine blood test during your annual physical predict deadly cancers in its earliest stages? A new Cambridge startup believes so.

Three researchers at Johns Hopkins University on Thursday launched Thrive Earlier Detection Corp. The startup has raised $110 million to test and commercialize its diagnostic device called CancerSEEK, which it believes can detect pieces of tumor DNA and cancer-associated proteins at a price point of a few hundred dollars.

The Series A round ranks as one of the…

Boston Biz Journal